In the second calendar quarter of 2003 (2Q 2003), UTMD’s earnings per share (eps) increased 14% to $.38, compared to $.33 in 2Q 2002. Eps for the first six months of 2003 (1H 2003) were $.75 compared to 1H 2002 eps of $.65, a 15% increase in year-to-date eps. Eps for the most recent four calendar quarters (LTM) were $1.46. LTM eps at the end of 2Q 2002 were $1.23. UTMD concluded its twenty-second consecutive quarter of higher eps compared to the same quarter in the prior year, during which 5½ year time span eps have grown at a compounded rate of 21% per year.

Consolidated worldwide sales were up 1% for 2Q 2003, and 2% for 1H 2003. The growth in sales was led by international sales, which were up 6% for 2Q 2003 and 12% for 1H 2003. UTMD achieved gross profit margins of 59.0% and 58.4% for the 2Q and 1H 2003 periods which were more than one percentage point higher than gross margins for the same periods in 2002. 2Q and 1H 2002 gross profit margins were were 57.6% and 57.3% respectively. UTMD continued to achieve outstanding operating profit margins of 39.6% and 39.5% for the 2Q and 1H 2003 periods, respectively. Operating margins for the same periods in 2002 were 38.3% and 37.9% respectively. Operating income dollars increased 4% in 2Q 2003 compared with 2Q 2002, and increased 6% for 1H 2003 compared with 1H 2002.

UTMD’s earnings before interest and income tax expenses and before non-cash depreciation/ amortization expenses (EBITDA), were $3,062,000 and $6,140,000 in 2Q and 1H 2003, compared to $3,047,000 and $6,005,000 in 2Q and 1H 2002, respectively. LTM EBITDA were $12,339,000. LTM EBITDA were 45% of sales, representing excellent operating performance.

UTMD previously projected it would eliminate its bank debt in the 3Q 2003. Because of increases in inventories, the Company now projects it will eliminate the debt early in 4Q 2003.

Financial ratios as of June 30, 2003 which may be of interest to investors include UTMD’s
     1) Current Ratio = 4.5
     2) Days in Receivables (based on 2Q sales activity) = 44.6
     3) Average Inventory Turns (based on 2Q CGS) = 3.0
     4) Year-to-Date ROE = 40.8%
These ratios meet or exceed management targets except for inventory turns. The company expects to steadily improve inventory turns during the remainder of 2003.

In response to shareholder requests for an update, UTMD continues to expect a decision by the U.S. Circuit Court of Appeals during this calendar year resolving the Tyco appeal of the September 2002 Federal District Court judgment awarding UTMD approximately $23 million in damages and accrued interest for patent infringement. Although the outcome of that decision is not predictable, UTMD remains confident in the merit of its position.

Investors are cautioned that this press release contains forward looking statements and that actual results may differ from those projected. Risk factors that could cause results to differ materially from those projected include GPOs limiting market access to potential customers, clinical acceptance of new and/or competitive products, timing of regulatory approval of new products, UTMD’s ability to efficiently manufacture, market, and sell its products, among other factors that have been outlined in UTMD’s public disclosure filings with the SEC. The 10-Q for the second quarter will be filed with the SEC by August 15, and will be available for direct access on the Internet for shareholders by linking through UTMD’s website www.utahmed.com.